Creative Medical Technology Holdings, Inc. (CELZ) P/E Ratio History
Historical price-to-earnings valuation from 2021 to 2021
Loading P/E history...
CELZ Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Creative Medical Technology Holdings, Inc. (CELZ) trades at a price-to-earnings ratio of -0.9x, with a stock price of $2.29 and trailing twelve-month earnings per share of $-2.31.
The current P/E is 452% below its 5-year average of 0.3x. Over the past five years, CELZ's P/E has ranged from a low of 0.3x to a high of 0.3x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, CELZ trades at a 104% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, CELZ trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CELZ DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CELZ P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 109.8 | 2.78 | +60% | |
| $8B | 25.5 | 1.11Best | -25% | |
| $548M | 11.5Lowest | - | +14% | |
| $21B | 25.5 | 6.01 | +171%Best | |
| $8B | 110.7 | - | -56% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
CELZ Historical P/E Data (2021–2021)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $22.10 | $85.65 | 0.3x | +0% |
Average P/E for displayed period: 0.3x
See CELZ's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CELZ Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CELZ vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCELZ — Frequently Asked Questions
Quick answers to the most common questions about buying CELZ stock.
Is CELZ stock overvalued or undervalued?
CELZ trades at -0.9x P/E, below its 5-year average of 0.3x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does CELZ's valuation compare to peers?
Creative Medical Technology Holdings, Inc. P/E of -0.9x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is CELZ's PEG ratio?
CELZ PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2021-2021.